[Nonalcoholic steatohepatitis, the enigma of bad progression].
Still, very little is known about the precise pathogenetic mechanisms, the triggering events and in particular, the evolution and treatment of nonalcoholic steatohepatitis (NASH). It is part of the broad spectrum of nonalcoholic fatty liver diseases (NAFLDs). Mainly, it has been reported as a benign disease, associated with metabolic disorders commonly occurrence en the general population. Nevertheless, the syndrome can lead to cirrhosis, liver failure or hepatocellular carcinoma, requiring liver transplantation. We present one patient with diagnosis of NASH, who was treated initially for overweight, HTA and hyperlipaemia with incompleted response and who showed a quickly progress to cirrhosis but no cause of liver decompensated disease could be identified. Currently she is at end-stage waiting a liver transplantation. Controlled and multicentric studies with the same definition of NASH and the study end-points are needed, and will provide information about diagnosis features and novel therapies to early management of the disease.
López Diéguez Puerta
M
M
Servicio de Medicina Interna, Hospital Universitario la Paz, Madrid. arialdp5@hotmail.com
Casal Esteban
V
V
Barbado Hernández
F J
FJ
Gil Guerrero
L
L
Rodríguez Molinero
M A
MA
Larrauri
J
J
Vázquez Rodríguez
J J
JJ
D000328:Adult; D018450:Disease Progression; D005234:Fatty Liver / Q000150:complications* / Q000473:pathology; D005260:Female; D006801:Humans